Half of US commercial health plans add coverage limits for gene and cell therapies beyond what they're approved for, ...

The study found that patients with luminal B subtype prostate cancer benefited from the addition of hormone therapy to ...

The drugmaker is transitioning to Trialbee's Honey platform to better screen patients, including for biomarker information, ...

The firm is testing the modified nucleotide drug ateganosine in a Phase II study with a PD-1 inhibitor in patients with non-small cell lung cancer.

VRise will develop and commercialize in India the BCMA/CD19-targeted KQ-2003, which is being studied as a treatment for multiple myeloma and POEMS syndrome.

In the meeting, the firm will discuss with the agency new, positive three-month data from the pediatric cohort of the Phase I/II OPGx-LCA5-1001 trial.

By leveraging EEG biomarkers, Alto Neuroscience seeks to target patient subgroups in psychiatry by matching therapies to biology.